News | June 21, 2022
India welcomes TRIPS waiver deal at WTO
TRIPS waiver for five years agreed in the recently concluded WTO will help countries manufacture COVID vaccines to deal with the pandemic
TRIPS waiver for five years agreed in the recently concluded WTO will help countries manufacture COVID vaccines to deal with the pandemic
With $120m jointly invested in the newly-formed initiative, and with other strategic investors expected to join, the venture will develop an alternative, plant-based ingredient using biotechnology
This investment will facilitate a Cipla entity's strategic participation in the Poe diagnostics and AMR space through the design, development, and manufacturing of microfluidics-based technologies
The company has a total sales of Rs. 25.8 crore during FY 21-22 and Rs. 26.4 crore during FY 20-21.
Revenues from operations for the full year ended March 31, 2022 stood at Rs. 590.05 crore as compared to Rs. 449.82 crore in FY21
Both manufacturing facilities are based out of Benguluru, India
Expanding diagnostics footprint in East India
Glenmark is the first company in India to market the innovative FDC of Indacaterol
Stelis's small-scale cGMP manufacturing facility is designed to support smallscale commercial and cGMP clinical trial material generation
48% of people are either hypertensive or at risk of becoming hypertensive & 30% of people have a high Waist Hip Ratio (WHR) – an early indication of the onset of CVDs
Subscribe To Our Newsletter & Stay Updated
